A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Clinical trial NCT04734262 · UNKNOWN
Trial details
- NCT number
- NCT04734262
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-01
- Primary completion
- 2024-06-30
- Enrollment
- 98
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.